相似文献
1
Golimumab.
MAbs. 2009 Sep-Oct;1(5):422-31. doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15.
2
Golimumab, a fully human monoclonal antibody against TNFalpha.
Curr Opin Mol Ther. 2008 Aug;10(4):393-406.
3
Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther. 2009 Jul 13;51(1316):55-6.
4
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
5
Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Clin Ther. 2010 Sep;32(10):1681-703. doi: 10.1016/j.clinthera.2010.09.003.
6
Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Isr Med Assoc J. 2012 Jun;14(6):390-4.
7
Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434.
8
Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49.
9
Golimumab, the newest TNF-α blocker, comes of age.
Clin Exp Rheumatol. 2015 Jul-Aug;33(4):570-7. Epub 2015 Jan 20.
10
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.
引用本文的文献
1
Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.
Psoriasis (Auckl). 2025 Jul 19;15:301-320. doi: 10.2147/PTT.S532062. eCollection 2025.
2
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
3
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss.
Pharm Res. 2025 Feb;42(2):353-363. doi: 10.1007/s11095-025-03825-3. Epub 2025 Feb 20.
4
Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.
Indian Dermatol Online J. 2024 Dec 26;16(1):50-58. doi: 10.4103/idoj.idoj_445_24. eCollection 2025 Jan-Feb.
5
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.
Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014.
6
Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Clin Rheumatol. 2023 Dec;42(12):3397-3405. doi: 10.1007/s10067-023-06760-z. Epub 2023 Sep 26.
7
Biologics and Biosimilars in Psoriasis.
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
8
Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.
J Clin Med. 2023 May 4;12(9):3271. doi: 10.3390/jcm12093271.
9
Therapeutic Strategies Targeting Pancreatic Islet β-Cell Proliferation, Regeneration, and Replacement.
Endocrinology. 2022 Nov 14;164(1). doi: 10.1210/endocr/bqac193.
10
Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.
Int J Mol Sci. 2022 Aug 16;23(16):9205. doi: 10.3390/ijms23169205.
本文引用的文献
1
E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
J Rheumatol. 2009 Jul;36(7):1371-9. doi: 10.3899/jrheum.080755. Epub 2009 Jun 1.
2
Tocilizumab: a review of its use in the management of rheumatoid arthritis.
Drugs. 2009;69(5):609-32. doi: 10.2165/00003495-200969050-00007.
3
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthritis Rheum. 2009 Apr;60(4):976-86. doi: 10.1002/art.24403.
4
Prospective new biological therapies for rheumatoid arthritis.
Autoimmun Rev. 2009 Dec;9(2):102-7. doi: 10.1016/j.autrev.2009.03.010. Epub 2009 Mar 26.
5
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.
Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8.
6
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9.
7
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.
8
Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-alpha in Cynomolgus Macaques.
J Immunotoxicol. 2005 Jul 1;1(3):131-9. doi: 10.1080/15476910490894904.
9
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
Arthritis Rheum. 2008 Apr;58(4):964-75. doi: 10.1002/art.23383.
10
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.
Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177.
Zotero 插件